Visit COVID-19 resources

[Skip to Content]

AMD

Survey finds nearly 70% of patients waiting too long for treatment

A survey of ophthalmologists found that nearly 70% of patients with wet age-related macular degeneration (AMD) had to wait more than the recommended two weeks for their first sight-saving injection. Many also wait too long for follow up treatment. The Royal College of Ophthalmologists and the Macular Society say their research shows that more resources

French health regulator reviews use of Avastin to treat AMD

College Statement The RCOphth notes with interest the move by the French health regulator, French National Agency for Medicines and Health Products Safety (ANSM), in asking Roche to provide information on the safety and efficiency of the off-label use of bevacizumab (Avastin) to treat wet age-related macular degeneration (AMD). Ranibizumab (Lucentis), which is licensed as

RCOphth recommends appraisal of the use of bevacizumab (Avastin) for age related macular degeneration

The Royal College of Ophthalmologists recommends UK regulatory bodies appraise the use of bevacizumab (Avastin) for age related macular degeneration potentially saving the NHS over £100million a year Age related macular degeneration (AMD) is the commonest cause of blindness among elderly people in the developed world1. The ageing population in the UK and associated eye

RCOphth invited to address All Party Parliamentary Group

‘Upskilled non-medically qualified professionals are needed as part of an ophthalmology led service to support an increase in capacity’ Miss Melanie Corbett, Consultant Ophthalmologist at Western Eye Hospital, Imperial College NHS Trust, London and Executive Committee Member of the RCOphth, spoke at a meeting of the All Party Parliamentary Group for Eye Health and Visual

Age-related Macular Degeneration

Age-related Macular Degeneration (AMD) is a long term condition which is the leading cause of sight loss in the UK. Sight loss often occurs quickly with the exudative (“wet”) form of AMD but can be stabilised or improved in most cases with prompt treatment and timely monitoring. The main objective for an AMD service is